What were Indoco Remedies Ltd's latest quarterly results?
Indoco Remedies Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -3.6%
- Revenue Growth YoY: +8.3%
- Operating Margin: 7.0%
Indoco Remedies Ltd: Stock Analysis & Fundamentals
Updated this weekIndoco Remedies Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. ROE: -7.0%. This stock is not currently in the Nifty 500 momentum outperformers list.
Key Numbers
Current Price
₹173
Dividend Yield
0.12%
Market Cap
1.6K Cr
Valuation
N/AOther Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Indoco Remedies Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Indoco Remedies Ltd's price-to-book ratio?
Indoco Remedies Ltd's price-to-book ratio is 1.6x.
- Price-to-Book (P/B): 1.6x
- Book Value per Share: ₹106
- Current Price: ₹173
Is Indoco Remedies Ltd a fundamentally strong company?
Indoco Remedies Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 0.0%
Is Indoco Remedies Ltd debt free?
Indoco Remedies Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹994 Cr
What is Indoco Remedies Ltd's return on equity (ROE) and ROCE?
Indoco Remedies Ltd's return ratios over recent years
- FY2023: ROCE 17.0%
- FY2024: ROCE 10.0%
- FY2025: ROCE 0.0%
Is Indoco Remedies Ltd's cash flow positive?
Indoco Remedies Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹95 Cr
- Free Cash Flow (FCF): ₹-244 Cr
What is Indoco Remedies Ltd's dividend yield?
Indoco Remedies Ltd's current dividend yield is 0.12%.
- Dividend Yield: 0.12%
- Current Price: ₹173
Who holds Indoco Remedies Ltd shares — promoters, FII, DII?
Indoco Remedies Ltd's shareholding pattern (Dec 2025)
- Promoters: 58.9%
- FII (Foreign): 1.1%
- DII (Domestic): 18.1%
- Public: 21.8%
Is promoter holding increasing or decreasing in Indoco Remedies Ltd?
Indoco Remedies Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 58.9% (Dec 2025)
- Previous Quarter: 58.9% (Sep 2025)
- Change: 0.00% (stable)
Is Indoco Remedies Ltd a new momentum entry or an established outperformer?
Indoco Remedies Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Indoco Remedies Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Indoco Remedies Ltd may be worth studying
- Cash flow is positive — CFO ₹95 Cr
What is the investment thesis for Indoco Remedies Ltd?
Indoco Remedies Ltd investment thesis summary:
What is the future outlook for Indoco Remedies Ltd?
Indoco Remedies Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.